BRIEF-Rallybio Announces Approval Of Clinical Trial Applications For Phase 2 Trial Of RLYB212 In Pregnant Women At Higher Risk Of Alloimmunization And FNAIT

Reuters10-29

Oct 29 (Reuters) - Rallybio Corp :

* RALLYBIO ANNOUNCES APPROVAL OF CLINICAL TRIAL APPLICATIONS FOR PHASE 2 TRIAL OF RLYB212 IN PREGNANT WOMEN AT HIGHER RISK OF ALLOIMMUNIZATION AND FNAIT

* RALLYBIO CORP - PHASE 2 TRIAL SCREENING TO INITIATE IN 4Q 2024

Source text: Further company coverage:

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment